BMS to trial Opdivo in solid tumours
pharmafile | July 30, 2015 | News story | Research and Development | BMS, Bristol-Myers Squibb, Kyowa Hakko Kirin, Poteligeo, mogamulizumab, nivolumab, opdivo, solid tumours
Bristol-Myers Squibb will begin early-phase trials of its immuno-oncology treatment Opdivo with other cancer treatments, to see if the combination can treat people with advanced solid tumours.
BMS it teaming up with the Japanese biopharma firm Kyowa Hakko Kirin to study Opdivo (nivolumab) in combination with Kyowa’s anti-cancer treatment Poteligeo (mogamulizumab).
The Phase I/II combination study will look at Poteligeo. The treatment is an anti-CCR4 antibody that has been available in Japan since May 2012 for the treatment of patients with relapsed or refractory CCR4-positive adult T-cell leukaemia-lymphoma (ATL), and has since added several other indications. Opdivo is a PD-1 immune checkpoint inhibitor that is available for advanced skin cancer and non-small cell lung cancer.
Both drugs are immunotherapies, which harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system.
The study will be conducted in the US and will focus on evaluating the safety and effectiveness activity of the combination as a potential treatment option for patients with advanced or metastatic solid tumours – such as sarcomas, carcinomas, and lymphomas.
The study will be run by Kyowa, and the firm’s board director and managing executive officer Yoichi Sato says: “We are pleased to conduct a combination study with Bristol-Myers Squibb not only in Japan but also in the US. We believe that the planned combination of these two immunotherapies has the potential to deliver better outcomes in patients with advanced cancers than existing treatments.”
While Michael Giordano, senior vice president and head of development, oncology, at Bristol-Myers Squibb says: “Today’s agreement builds on our initial collaboration with Kyowa Hakko Kirin in Japan, which includes our partner Ono Pharmaceutical, and is the latest example of our continued commitment to evaluating the potential of combination immuno-oncology regimens for patients with metastatic cancer.”
Lilian Anekwe
Related Content
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products …
Fate Therapeutics initiates phase 1 trial for solid tumour treatment
Fate Therapeutics has announced that it has begun enrollment for the phase 1 clinical trial …
Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …
